ALPG

ALPG

ALPG Molekülinformation

Molecule Name
Alkaline phosphatase
Molekülalias
ALPG,GCAP,ALP-1,ALPPL2,PLAP-like,ALPPL,Alkaline phosphatase, germ cell type
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
Alkaline Phosphatase
Molekülhintergrund
ALPPL2 is specifically highly expressed in naïve pluripotent stem cells. Moreover, in naïve state somatic cell reprogramming, naïve-primed transformation and other systems, the use of the ALPPL2 promoter-driven fluorescent reporter system can specifically indicate the establishment or withdrawal of naïve state pluripotency, thereby identifying ALPPL2 as naïve state pluripotent. specific cell surface markers. Some studies have found that knockout of ALPPL2 can specifically affect the establishment, stability and maintenance of naïve state pluripotency, proving that ALPPL2 protein is a functional naïve state surface molecular marker.

ALPG Produktliste

Species
  • Human(2)
  • Mouse(1)
Tag
  • His Tag(2)
  • His Tag & Avi Tag(1)
Host
  • HEK293(3)
Conjugate
  • Unconjugated(2)
  • Biotin-labeled(1)
Grade
  • RUO(3)
Low Endotoxin
  • Yes(1)
  • No(2)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
ALPG
Human ALPG / ALPPL2 Protein, His Tag, low endotoxin (active enzyme, MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAEnzyme

$470.00

100ug
ALPG
Avitag
ALG-H52E1
Biotinylated Human ALPG / ALPPL2 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
ALPG
Mouse ALPG / ALPPL2 Protein, His Tag (active enzyme, MALS verified)
Mouse
HEK293
MALSSDS-PAGE
Enzyme

$410.00

100ug
You Have Viewed 1-3 Of 3 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Antikörperprojekt-Handelsplattform

ProjektnameProjektphaseMolekültypMolekülquelleKrankheitsgebietIndikationen
ALPP/ALPPL2 mAb - 01PCCMonoclonalHumanized MouseSolid TumorEndometrial cancer,Ovarian cancer
Projektphase
PCC
Molekültyp
Monoclonal
Molekülquelle
Humanized Mouse
Krankheitsgebiet
Solid Tumor
Indikationen
Endometrial cancer,Ovarian cancer
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
ALXN-1850ALXN-1850Phase 3 ClinicalAlexion Pharmaceuticals Inc
Hypophosphatasia
Details
Amifostine for nasoduodenal delivery (Xerient Pharma)XER-001Phase 2 ClinicalXerient Pharma
Pancreatic Neoplasms
Details
placenta-derived protein (Zoltan)PALPClinicalZoltan Laboratories
Cachexia; Diabetes Mellitus; Obesity
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
AmifostineWR-2721C; NSC-296961; YM-08310; S-8744; SAPEP; WR-2721ApprovedMedimmune LlcEthyol, 天地达, 安福定Mainland ChinaCytoprotective adjuvantChina Grand Automotive Services Group Co Ltd1995-12-08
Acute Radiation Syndrome; Bone Marrow Diseases; Breast Neoplasms; Carcinoma; Cytoprotective adjuvant; Fanconi Anemia; Gestational Trophoblastic Disease; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Mucositis; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nasopharyngeal Neoplasms; Neurotoxicity Syndromes; Neutropenia; Ovarian Neoplasms; Peripheral Nervous System Diseases; Prostatic Neoplasms; Salivary Gland Diseases; Sarcoma; Solid tumours; Trigeminal Neuralgia
Details
Customer Reviews